Table 1.
Demographic and clinical characteristics of patients with IBS and SIBO
| Characteristics | All patients (N = 98) | IBS with SIBO (n = 35) | Odds ratio* (95% CI) |
|---|---|---|---|
| Age >55 y, n (%) | 28 (29) | 16 (46) | 3.6 (1.4-9.0) |
| Female, n (%) | 76 (78) | 32 (91) | 4.0 (1.1-14.5) |
| IBS subtype, n (%) | |||
| IBS-C | 51 (52) | 19 (54) | 1.2 (0.5-2.6) |
| IBS-D | 38 (39) | 15 (43) | 1.3 (0.6-3.0) |
| IBS-A | 9 (9) | 1 (3) | 0.2 (0.02-1.7) |
| Medications,** n (%) | |||
| Tegaserod | 15 (15) | 6 (17) | 1.1 (0.4-3.3) |
| Opiate analgesic | 38 (39) | 13 (37) | 1.0 (0.4-2.3) |
| Proton pump inhibitor | 21 (21) | 7 (20) | 0.8 (0.3-2.1) |
IBS: irritable bowel syndrome; SIBO: small intestinal bacterial overgrowth; CI: confidence interval; IBS-C: constipation-predominant IBS; IBS-D: diarrhea-predominant IBS; IBS-A: alternating IBS.
*Comparing patients with IBS versus patients with IBS and SIBO, **Previous and current use of specific IBS therapy.